Understanding the Impact of New Developments at FDA on the IP Due Diligence Review Process
This session aims to answer the following questions:
- Which RNA therapeutics are likely to qualify for 12-year exclusivity?
- What does Braeburn v. FDA mean for the scope of 3-year exclusivity?
- How will FDA assess whether gene or cell therapies are the “same drug” for orphan drug purposes?